Estrella Immunopharma, Inc.
For the period ended Dec 31, 2025. Filed Mar 18, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 18, 2026
ESLA$0.75+45.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
| For the Year Ended December 31, 2025 · For the Six Months Ended December 31, 2024 | ||||
|---|---|---|---|---|
| (Short Year) | ||||
| Cash Flows from Operating Activities: | ||||
| Net loss | $(13,063,512) | $(4,427,027) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Stock-based compensation | 618,974 | 432,256 | ||
| Change in fair value of derivative liabilities | 38,189 | - | ||
| Changes in operating assets and liabilities: | ||||
| Prepaid expenses and other receivable | 431,188 | (435,100) | ||
| Prepaid expenses - related party | - | (1,500,000) | ||
| Accounts payable - related party | 550,346 | 4,435 | ||
| Other payables and accrued liabilities | 36,654 | 69,937 | ||
| Accrued liability - related party | 9,606,666 | 2,782,667 | ||
| Franchise tax payable | (4,134) | - | ||
| Income tax payables | (50) | (40,694) | ||
| Net cash used in operating activities | (1,785,679) | (3,113,526) | ||
| Cash Flows from Financing Activities: | ||||
| Payments of transactions cost | (117,473) | - | ||
| Proceeds from issuance of common stock through stock purchase agreement | - | 79,491 | ||
| Proceeds from issuance of common stock for PIPE investment | 2,400,000 | - | ||
| Purchase of treasury stock | (29,462) | (214,477) | ||
| Net cash provided by (used in) financing activities | 2,253,065 | (134,986) | ||
| Net Change in Cash | 467,386 | (3,248,512) | ||
| Cash at beginning of the year | 916,916 | 4,165,428 | ||
| Cash at end of the year | $1,384,302 | $916,916 | ||
| Supplemental Cash Flow Information | ||||
| Cash paid for income tax | $913 | $42,366 | ||
| Cash paid for interest | $ | - | $ | - |
| Supplemental Disclosure of Non-cash Financing Activities | ||||
| Recognition of derivative liabilities upon closing of the PIPE investment | $318,316 | $ | - | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.